News BioNTech to buy rival mRNA firm CureVac for $1.25bn BioNTech has agreed to buy another specialist in mRNA medicines, fellow German biotech CureVac, for around $1.25 billion.
News MSD aims to plug dengue fever vaccine gap in US MSD is preparing to take on Takeda in the dengue fever vaccine market, moving its V181 candidate into phase 3.
News Novo Nordisk teams up with NVIDIA on AI models Novo Nordisk and tech giant NVIDIA have joined forces on a new project that aims to speed up drug discovery using generative AI.
News SpliceBio gathers $135m for eye disease gene therapies Spain's SpliceBio has raised $135m in financing that will help it move a gene-editing therapy for Stargardt disease through clinical testing.
News NewAmsterdam says lead drug may have Alzheimer's role NewAmsterdam has said that an oral drug it is developing to lower cholesterol has shown early efficacy as a preventive therapy for Alzheimer's.
News MSD moves ahead in race to bring oral PCSK9 drug to market Armed with positive results in two phase 3 trials, MSD is poised to be the first to file for approval of an oral PCSK9 drug to lower cholesterol.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
